AMES, Iowa, June 28 /PRNewswire-FirstCall/ -- BioForce Nanosciences (OTC Bulletin Board: BFNH), which develops and markets commercial products for nanotechnology applications, has announced that Dr. Guenter H. Jaensch and Kerry Frey, BioForce's chief operating officer, have joined the company's board. Jaensch is a former executive at Siemens, where he held positions both in Europe and the US. During his more than 25 years with Siemens, he served as president of Siemens Communications, Inc., chairman & president of Siemens Corporate Research and Support, Inc., and chairman and CEO of Siemens Pacesetter, Inc. When St. Jude Medical, Inc., acquired Siemens Pacesetter in 1994, Jaensch was key to the transition process and stayed as chairman and CEO of Pacesetter, Inc., a St. Jude Medical Company, until 1995. Since 1997, Jaensch has been a director of MRV Communications, Inc., a leading company in the fiber optic technology business; since 2002 he has served as chairman of the Board of Biophan Technologies, Inc. "There is a great deal of noise about nanotechnology in the market but so far only very few practical applications," Jaensch said. "With its NanoArrayer System, BioForce offers exciting and immediately usable tools for the growing field of bionanotechnology." Frey joined BioForce earlier this year with more than 30 years of broad-based management and operational experience in the medical device, pharmaceutical and healthcare industries. Over the course of his career, he has developed and implemented innovative and profitable new products, programs and services with such companies as Medisys Technologies and Johnson and Johnson. "I am excited about working with the people at BioForce as we bring innovative new products to the marketplace and continue to position the company in the forefront of the bionanotechnology industry," Frey said. "Both Guenter and Kerry bring a wealth of experience to BioForce," said Dr. Eric Henderson, founder and CEO. "They will be invaluable additions as we continue to build on our technology and look to enhance shareholder value as we grow our company." About BioForce Nanosciences, Inc. BioForce Nanosciences provides innovative and practical commercial products for applications in nanotechnology, with more than a decade of invention, research and development of patented and patent-pending products. The core technology is the NanoArrayer(TM) System, a proprietary platform for precision printing and surface patterning. The NanoArrayer(TM) System includes a consumable line of print cartridges and chip surfaces. This system enables new and important applications in the biomedical and life sciences markets. BioForce continues to target inventions that further expand the reach of its proprietary technology. The ViriChip(TM) System, a patented diagnostic device for rapid detection and identification of multiple viruses on a single chip, is an example of the Company's technology expansion program. BioForce Nanosciences, Inc., the Practical Nanotechnology(TM) company, brings inventions to the marketplace that complement existing innovations, licensing and acquisitions. BioForce is a wholly owned subsidiary of BioForce Nanosciences Holdings, Inc. (OTC Bulletin Board: BFNH.OB). For more information, visit http://www.bioforcenano.com or contact BioForce at email@example.com or 515-233-8333.
SOURCE BioForce Nanosciences